TCRX: Tscan Therapeutics Inc Company Profile & Statistics

About

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

Info & Links

CEO

Gavin MacBeath

Headquarters

830 WINTER STREET
WALTHAM, MA 02451, UNITED STATES

Auditor

Deloitte & Touche LLP

Share holders

Employees

154

Tscan Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

160.11M

Enterprise Value

57.64M

Enterprise Value/EBITDA(ttm)

-0.50

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

16.25

Price to Book(mrq)

0.66

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1188.88%

Profit Margin(ttm)

-3588.36%

Return on Equity(ttm)

-58.72%

Return on Invested Capital(ttm)

-54.64%

Return on Assets(ttm)

-36.02%

Income Statement

Revenue(ttm)

9.36M

Revenue Per Share(ttm)

0.18

Gross Profit(ttm)

9.36M

EBITDA(ttm)³

-114.79M

Net Income Available to Common(ttm)

-111.30M

Diluted EPS(ttm)

-1.06

Share Statistics

Beta (5Y Monthly)

0.79

52-Week Change

-50.98%

S&P 500 52-Week Change

27.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

53.37M

Dividend Yield

0.00%

Float⁴

51.90M

% Held by Insiders

2.76%

% Held by Institutions

82.83%

Balance Sheet

Total Cash(mrq)

271.12M

Total Cash Per Share(mrq)

5.08

Total Debt(mrq)

30.65M

Total Debt/Equity(mrq)

13.38%

Current Ratio(mrq)

9.56%

Quick Ratio(mrq)

9.56%

Book Value Per Share(mrq)

4.29

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.70

Free Cash Flow(ytd)

-86.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

TCRX

Tscan Therapeutics Inc

Tscan Therapeutics Inc Profile